A Randomized, Double-Blind, Parallel-Group, 12-Week, Chronic Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 31 May 2017 Planned End Date changed from 7 Dec 2017 to 7 Dec 2018.
- 31 May 2017 Planned primary completion date changed from 7 Dec 2017 to 7 Dec 2018.
- 31 May 2017 Planned initiation date changed from 14 Apr 2017 to 16 Apr 2017.